Adcendo is a global clinical-stage biotech company dedicated to developing transformative first- and potential best-in-class antibody-drug conjugate (ADC) therapies targeting cancers with high unmet medical need. Led by a team of experienced biopharma executives with a track record of advancing multiple ADCs to approval, Adcendo integrates novel targets, optimized linker-payload combinations, and a rationally designed development strategy to drive next-generation cancer therapies. Designed for Precision. Developed for Life. Read more at www.adcendo.com
| Website | http://adcendo.com |
| Employees | 66 (46 on RocketReach) |
| Founded | 2017 |
| Technologies | |
| Industry | Biotechnology Research, Biotechnology, Drug Discovery, Science and Engineering, Pharmaceuticals |
| Keywords | Antibody Drug Conjugates, Biotechnology, First In Class, Therapeutic Antibodies, Clinical Stage, Solid Tumor Therapy, Targeted Therapy, Cancer Treatment, Drug Development, Immunotherapy, New Drug Development, Clinical Trials, Drug Discovery, Oncology, Biopharma, Precision Medicine, Cancer Research, Pharmaceutical, Biologics |
| Competitors | Novartis, Bristol Myers Squibb, Amgen, Regeneron, Gilead Sciences, bluebird bio, Atara Biotherapeutics, Celyad Oncology, CBMG Holdings, Carisma Inc. +33 more (view full list) |
Looking for a particular Adcendo employee's phone or email?
Adcendo Questions
Michael Pehl is the CEO of Adcendo.
46 people are employed at Adcendo.
Top Adcendo Employees
-
Michael Pehl
CEO at Adcendo
København, DK24 -
Lars Engelholm
Co-Founder at Adcendo
Copenhagen, DK2 -
Pernille Hemmingsen
Chief Technology Officer at Adcendo
Copenhagen, DK1 -
Fang Ni
Chief Financial Officer at Adcendo
United States35 -
11
-
Lasse Sørensen
General Manager | VP of Operations at Adcendo
Copenhagen, DK2 -
22
-
Lars Dreiøe
Vice President Quality at Adcendo
Copenhagen, DK13 -
Jared Lurk
Vice President, Head of U.S. Medical Affairs at Adcendo
St. Louis, MO, US23 -
21
Related Companies
